Kelyniam Global Reports 2025 Financial Results
PR Newswire —
Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusion™ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants,...